Revisiting 5α-reductase inhibitors and the risk of prostate cancer

被引：10
|
作者：
Chau, Cindy H. [1 ]
Figg, William D. [1 ]
机构：
[1] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
NATURE REVIEWS UROLOGY | 2018年 / 15卷 / 07期
基金：
美国国家卫生研究院;
关键词：
FINASTERIDE; MORTALITY; MEN;
D O I：
10.1038/s41585-018-0018-9
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The role of 5 alpha-reductase inhibitors (5-ARI) in prostate cancer chemoprevention remains a controversy, as cancer prevention trials with 5-ARIs have shown a decreased incidence of low-grade prostate cancer but a potential increased risk in high-grade disease. Recent studies have shed light on the long-term safety of 5-ARIs in terms of influencing prostate cancer risk.
引用
收藏
页码：400 / 401
页数：3
相关论文
共 50 条
  • [31] 5-alpha reductase inhibitors and PSA screening for prostate cancer
    Zardawi, Ibrhahim M.
    [J]. PATHOLOGY, 2014, 46 (01) : 91 - 91
  • [32] The utility of 5-α reductase inhibitors in the prevention and diagnosis of prostate cancer
    Reed, Amanda Beth
    Parekh, Dipen J.
    [J]. CURRENT OPINION IN UROLOGY, 2009, 19 (03) : 238 - 242
  • [33] Benefits of Targeted Use of 5α-Reductase Inhibitors in Patients With Prostate Cancer
    Gann, Peter H.
    [J]. JAMA INTERNAL MEDICINE, 2019, 179 (10) : 1441 - 1441
  • [34] Guideline for 5-α-Reductase Inhibitors in the Prevention of Prostate Cancer Is Premature
    Frankel, Paul H.
    Twardowski, Przemyslaw
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : E164 - E164
  • [35] The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
    Theoret, Marc R.
    Ning, Yang-Min
    Zhang, Jenny J.
    Justice, Robert
    Keegan, Patricia
    Pazdur, Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (02): : 97 - 99
  • [36] 5α-Reductase 2 polymorphisms as risk factors in prostate cancer
    Söderström, T
    Wadelius, M
    Andersson, SO
    Johansson, JE
    Johansson, S
    Granath, F
    Rane, A
    [J]. PHARMACOGENETICS, 2002, 12 (04): : 307 - 312
  • [37] 5-ALPHA REDUCTASE INHIBITORS AND THE RISK OF PROSTATE CANCER MORTALITY IN MEN TREATED FOR BENIGN PROSTATIC HYPERPLASIA
    Wallner, Lauren
    DiBello, Julia
    Li, Bonnie
    Van Den Eeden, Stephen
    Weinmann, Sheila
    Ritzwoller, Debra
    Abell, Jill
    D'Agostino, Ralph, Jr.
    Loo, Ronald
    Aaronson, David
    Richert-Boe, Kathryn
    Horwitz, Ralph
    Jacobsen, Steven
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E27 - E28
  • [38] Role of 5-alpha-reductase inhibitors in active surveillance of patients with low-risk prostate cancer
    Chiang, Andrew Szehsun
    Loblaw, D. Andrew
    Jethava, Vibhuti
    Sethukavalan, Perakaa
    Zhang, Liying
    Vesprini, Danny
    Mamedov, Alexandre
    Nam, Robert
    Klotz, Laurence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [39] Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer
    Ross, Ashley E.
    Feng, Zhaoyong
    Pierorazio, Phillip M.
    Landis, Patricia
    Walsh, Patrick C.
    Carter, H. Ballentine
    Trock, Bruce J.
    Schaeffer, Edward M.
    [J]. BJU INTERNATIONAL, 2012, 110 (05) : 651 - 657
  • [40] 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia
    Wallner, Lauren P.
    DiBello, Julia R.
    Li, Bonnie H.
    Van Den Eeden, Stephen K.
    Weinmann, Sheila
    Ritzwoller, Debra P.
    Abell, Jill E.
    D'Agostino, Ralph, Jr.
    Loo, Ronald K.
    Aaronson, David S.
    Richert-Boe, Kathryn
    Horwitz, Ralph I.
    Jacobsen, Steven J.
    [J]. MAYO CLINIC PROCEEDINGS, 2016, 91 (12) : 1717 - 1726
12345